Clinical trials
First Line Therapy clinical trials
Below are recruiting first line therapy clinical trials, each written for real people, not researchers. We’re tracking 450 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06646497RecruitingPhase 2
Stem cell transplant for tough aplastic anemia in adults 40-60
This study is testing whether a stem cell transplant (from a matched relative, unrelated donor, or half-matched donor) can help adults aged 40–60 with severe aplastic anemia that didn't get better or came back after standard treatments.
Paris, FranceAges 40–60 - NCT04527055Enrolling by invitationPhase 4
Bismuth treatment for H. pylori: 10 or 14 days
This trial compares two common stomach medicine plans that use bismuth for 10 days versus 14 days to clear an H. pylori infection. It may help you find a shorter or more effective treatment schedule if you have H. pylori confirmed by an endoscopy.
TainanAges 18–100 - NCT04055220Recruiting
Regorafenib to keep bone cancer from coming back
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
BesançonAges 12 years+ - NCT04713670RecruitingPhase 4
Tested medicines to cure new H. pylori infection
This trial compares different stomach-medicine combinations to eliminate a new (first-time) H. pylori infection. It may help find the most effective treatment approach for people who have never tried eradication therapy before.
TaipeiAges 20 years+ - NCT07815834RecruitingPhase 3
FAPI-guided radiation with cadonilimab and chemo for colorectal cancer spread to the abdomen
This trial tests a new combination treatment for colorectal cancer that has spread only to the lining of the abdomen (peritoneum). It combines targeted radiation, an immunotherapy drug called cadonilimab, and standard chemotherapy to see if it can help control the disease better than current options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05894694RecruitingPhase 4
Testing Compound Kushen injection for advanced colon cancer survival
This trial studies whether Compound Kushen injection can improve survival in people with advanced colorectal cancer. It’s aimed at people starting first-line treatment, and only includes certain cancer and health situations to keep results clear.
BeijingAges 18 years+ - NCT07827716RecruitingPhase 2
Testing terfenadine for relapsing multiple sclerosis
This study tests whether terfenadine, an allergy medicine, is safe and helpful for people with relapsing-remitting multiple sclerosis (MS). It may reduce MS activity and improve outcomes.
Wuhan, HubeiAges 18–65 - NCT06232083RecruitingPhase 1
Study of Caronizumab with low-dose radiation for certain cancers
This trial tests a combination of an immunotherapy drug (Caronizumab) and a special type of low-dose radiation (PLDR) for people with esophageal, lung, or cervical cancer that has come back or spread after initial treatment. It aims to see if the combination can help stop the cancer from growing.
Hefei, British ColumbiaAges 18–75 - NCT06588322Recruiting
Detecting gene changes in blood of ovarian cancer patients on PARP inhibitor
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
AngersAges 18 years+ - NCT07530445RecruitingPhase 2
Immunotherapy plus chemotherapy for advanced biliary tract cancer
This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted drug (lenvatinib) for biliary tract cancer that has spread or cannot be surgically removed. The goal is to slow cancer growth in patients whose cancer has progressed after one prior treatment.
GuangzhouAges 18–70 - NCT06405490RecruitingPhase 2
Chemo plus immunotherapy for first-line advanced pancreatic cancer
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07500298RecruitingPhase 1
New drug plus standard chemo for spread colorectal cancer
This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.
Houston, TexasAges 18 years+ - NCT06981325RecruitingPhase 2
Cemiplimab for advanced basal cell carcinoma
This trial tests cemiplimab, an immunotherapy drug, as a first treatment for advanced basal cell carcinoma that cannot be removed with surgery or radiation. The goal is to see if it can shrink or control the cancer.
ErfurtAges 18 years+ - NCT05838066RecruitingPhase 3
KN026 plus HB1801 for HER2-positive advanced breast cancer
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
Beijing, chaoyangAges 18 years+ - NCT07101744RecruitingPhase 2
Drug combination study for advanced nasopharyngeal cancer
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
GuangdongAges 18–70 - NCT06768307RecruitingPhase 2
Adebrelimab + Chemo with Radiation for Extensive-Stage SCLC
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07407231Recruiting
Chemo and radiation for advanced inoperable pancreatic cancer
This trial tests a combined treatment of chemotherapy followed by a precise type of radiation therapy (SBRT) for people with pancreatic cancer that cannot be surgically removed. It is designed for those who have not yet started treatment for locally advanced disease.
LjubljanaAges 18 years+ - NCT06830018Recruiting
New megestrol for advanced stomach or colon cancer with fatigue
This study tests a new form of megestrol (a medicine that can boost appetite and energy) for people with advanced stomach or colorectal cancer who also have fatigue and poor appetite. It is given as a first treatment, meaning you haven't had chemotherapy yet for your advanced cancer.
Shenyang, LiaoningAges 18–75 - NCT07207278Recruiting
Genetics and immune study of lung signet ring cell cancer
This research study is looking at the unique genetic makeup and immune features of a rare type of lung cancer called signet ring cell carcinoma. By studying tumor samples and medical data, researchers hope to find better ways to understand and eventually treat this cancer.
Hangzhou, ZhejiangAges 18–85 - NCT07470996Recruiting
T-cell lymphoma treatment after first therapy fails
This trial is for people with certain T-cell lymphomas that did not respond or got worse after initial chemotherapy. It offers a personalized treatment plan, possibly including a stem cell transplant, based on how your disease behaved after first-line therapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06123494RecruitingPhase 3
A trial of SHR-A1811 for HER2-positive gastric cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06805812Recruiting
Predicting outcomes of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
AvianoAges 18 years+ - NCT07353840Recruiting
Personalized treatment for T-cell lymphoma after first complete remission
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07122024RecruitingPhase 4
Testing a dual therapy for H. pylori treatment
This trial tests a two-drug treatment (keverprazan and amoxicillin) for people who have H. pylori and have not been treated for it before. The goal is to see if this newer combination works well and is safe.
Hangzhou, ZhejiangAges 18–65
Hear when a new First Line Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first line therapy?
- Yes. Clin2 currently lists 450 recruiting first line therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first line therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first line therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.